Gifted by god?
Gifted by god?
-
-
Global Afamelanotide Market (2024–2032): USD 136.27M to USD 258.01M Growth at 9.1% CAGR
Global Afamelanotide Market is expected to grow from USD 136.27 million in 2024 to USD 258.01 million by 2032, registering a strong CAGR of 9.1% during 2025–2032. Market expansion is fueled by rising cases of rare phototoxic disorders such as Erythropoietic Protoporphyria (EPP), increased awareness about orphan diseases, and advancements in melanocortin-based peptide therapies.Afamelanotide, marketed as SCENESSE®, is the first and only FDA- and EMA-approved treatment for EPP. By stimulating melanin production, it offers significant photoprotection and improves sunlight tolerance, making it a breakthrough therapy for patients suffering from severe light sensitivity. Clinical pipelines exploring applications in vitiligo, photodermatoses, and select neurological disorders are further expanding market potential.
Global Afamelanotide Market (2024–2032): USD 136.27M to USD 258.01M Growth at 9.1% CAGR Global Afamelanotide Market is expected to grow from USD 136.27 million in 2024 to USD 258.01 million by 2032, registering a strong CAGR of 9.1% during 2025–2032. Market expansion is fueled by rising cases of rare phototoxic disorders such as Erythropoietic Protoporphyria (EPP), increased awareness about orphan diseases, and advancements in melanocortin-based peptide therapies.Afamelanotide, marketed as SCENESSE®, is the first and only FDA- and EMA-approved treatment for EPP. By stimulating melanin production, it offers significant photoprotection and improves sunlight tolerance, making it a breakthrough therapy for patients suffering from severe light sensitivity. Clinical pipelines exploring applications in vitiligo, photodermatoses, and select neurological disorders are further expanding market potential.
0 Σχόλια ·0 Μοιράστηκε ·176 Views ·0 Προεπισκόπηση
